Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1994 Jul;12(9):805-11.
doi: 10.1016/0264-410x(94)90289-5.

Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection

Affiliations
Comparative Study

Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection

P Roy et al. Vaccine. 1994 Jul.

Abstract

Insect cells co-infected with appropriate recombinant baculoviruses synthesize double-shelled, virus-like particles (VLPs) with bluetongue virus (BTV) VP2 proteins representing serotype 1 (BTV-1), 2 (BTV-2), 10 (BTV-10), 13 (BTV-13) or 17 (BTV-17) as previously reported for BTV-10 (French, T.J., Marshall, J.J.A. and Roy, P. J. Virol. 1990, 64, 5696-5700). The derived particles were purified and used to vaccine sheep, either as single VLP types (BTV-10, BTV-17) or as a combination of all five serotypes. Control sheep received saline. The virus-neutralizing antibody responses were measured. Depending on the experiment, the sheep were challenged with homologous (BTV-10, -13, -17) or selected heterologous (BTV-4, -11, -16) viruses either after 4 months or 14 months, and the disease, viraemias and clinical reactions monitored. The results indicated that two doses of 10 micrograms of VLPs elicited a long-lasting immune response which protected the sheep against challenge with the homologous virulent virus. In certain cases, partial protection was afforded against challenge by heterologous BTV serotypes.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources